The The Impact of Surgical Revascularization on Cardiac Function and Mitral Regurgitation in Patients with Coronary Artery Disease: An Intermediate-Term Single-Center Experience.

INTRODUCTION: Ischemic heart disease is the most common cause of death worldwide. Coronary artery bypass grafting (CABG) is the most performed cardiac surgical procedure. Studies have shown that CABG can have a beneficial effect on left ventricular ejection fraction (LVEF) and ischemic mitral regurgitation (IMR) without intervention on the mitral valve. This study aims to assess changes in LVEF and IMR after CABG in our population. METHODS: We retrospectively reviewed charts of patients who underwent only CABG at King Faisal Cardiac Center in Jeddah between January 2016 and December 2019 (N = 298). Pre- and postoperative echocardiography data were evaluated. Changes in cardiac function and mitral regurgitation were analyzed. RESULTS: CABG was performed on 298 patients. The median age was 61 years (interquartile range (IQR)= 54-68), and 78.5% of the patients were male. The median body mass index was slightly higher in females (32.9 vs. 28.6 kg/m2, P = 0.089). Approximately 81% of patients had diabetes and hypertension, but only 24% were active smokers. The median time between pre- and postoperative echocardiography was 8 months (IQR= 3-17). The median preoperative LVEF was 51% (IQR= 44.1-57.9), and 75% of patients had normal-to-mild MR. The median postoperative EF was not different among patients who underwent echocardiography within or after 6 months (53.1% and 50.3%, respectively, P = 0.454). None of the patients progressed to severe MR after surgery, and only 2.7% had moderate-to-severe MR at follow up. Postoperative in-hospital mortality was 0.7%. CONCLUSION: Based on international guidelines and the best evidence, surgical revascularization is sufficient for patients with coronary artery disease (CAD) with moderate IMR and is not associated with LVEF worsening or MR progression. Complete revascularization might have an influence on ventricular recovery that might improve or stabilize IMR. Our results are consistent with larger studies reporting very low postoperative mortality of this high-risk patient group.

Impact of coronary artery disease on outcomes after transcatheter aortic valve implantation.

BACKGROUND: Coronary artery disease (CAD) negatively impacts prognosis of patients undergoing surgical aortic valve replacement and revascularization is generally recommended at the time of surgery. Implications of CAD and preprocedural revascularization in the setting of transcatheter aortic valve implantation (TAVI) are not known. METHOD: Patients who underwent successful TAVI from January 2005 to December 2007 were retrospectively divided into five groups according to the extent of CAD assessed with the Duke Myocardial Jeopardy Score: no CAD, CAD with DMJS 0, 2, 4, and > or =6. Study endpoints included 30-day and 1-year survival, evolution of symptoms, left ventricular ejection fraction (LVEF), and mitral regurgitation (MR) and need of revascularization during follow-up. RESULTS: One hundred and thirty-six patients were included, among which 104 (76.5%) had coexisting CAD. Thirty-day mortality in the five study groups was respectively 6.3, 14.6, 7.1, 5.6, and 17.7% with no statistically significant difference between groups (P = 0.56). Overall survival rate at one year was 77.9% (95% CL: 70.9, 84.9) with no difference between groups (P = 0.63). Symptoms, LVEF, and MR all significantly improved in the first month after TAVI, but the extent of improvement did not differ between groups (P > 0.08). Revascularization after TAVI was uncommon. CONCLUSION: The presence of CAD or nonrevascularized myocardium was not associated with an increased risk of adverse events in this initial cohort. On the basis of these early results, complete revascularization may not constitute a prerequisite of TAVI. This conclusion will require re-assessment as experience accrues in patients with extensive CAD.

CT of the ilio-femoral arteries using direct aortic contrast injection: proof of feasibility in patients screened towards percutaneous aortic valve replacement.

PRINCIPLES: Transfemoral aortic valve implantation (TAVI) is a promising treatment modality for selected patients with severe symptomatic aortic stenosis. Peripheral access via the femoral and iliac artery is an important issue, limiting this technique's applicability in patients suffering from peripheral arterial disease. Multislice computed tomography (MSCT) reliably identifies patients with suitable peripheral access. However, MSCT involves an additional contrast dye burden in patients often suffering from renal failure. In this study, the feasibility of direct-aortic-contrast-injection for MSCT was investigated, aiming to reduce total contrast load. METHODS: Patients undergoing evaluation for TAVI underwent an aortogram including iliac and femoral arteries. In 7 selected patients with questionable peripheral access, MSCT was performed by advancing a pigtail catheter to the level of L2, followed by direct injection of 15-20 ml of contrast mixed with an equal volume of saline. This injection was followed by an injection of 40 ml of saline. Scanning was initiated 4 seconds after starting the contrast injection. All MSCT scans were obtained using a 64 slice scanner. RESULTS: In all 7 patients, except one, the distal aorta, iliac and femoral arteries where adequately imaged to allow reliable assessment of peripheral access for TAVI. Of the 7 patients evaluated, 2 were rejected for TAVI based on the information of the MSCT using direct-aortic-contrast-injection. Limitations of the technique may be an underestimation of the arterial diameter due to spasms at the puncture site. CONCLUSION: MSCT using direct-aortic-contrast-injection for assessment of peripheral access for TAVI is feasible and may provide good diagnostic images with a reduced volume of contrast.

The evolving role of MDCT in transcatheter aortic valve replacement: a radiologists' perspective.

OBJECTIVE: The purpose of this article is to familiarize the radiologist with the technical aspects of transcatheter aortic valve replacement (TAVR). The wide range of MDCT imaging findings that are critical for planning and performing TAVR will be reviewed. CONCLUSION: TAVR is developing into an effective and reproducible therapy for aortic valve stenosis. We describe the important role of MDCT in planning and performing TAVR in a large transcatheter valve program.

A new transcatheter aortic valve and percutaneous valve delivery system.

OBJECTIVES: We describe procedural and clinical outcomes in a high-risk cohort undergoing transcatheter aortic valve replacement with early next-generation transcatheter valve and delivery systems. BACKGROUND: Percutaneous aortic valve replacement is gaining acceptance as a viable option in patients at high surgical risk. Broader application will require further advances in valve and delivery system technology. METHODS: Transarterial aortic valve replacement was attempted in 25 patients (mean age 85 years) determined to be at high surgical risk due to comorbidities. A new delivery catheter system (RetroFlex 2, Edwards Lifesciences, Irving, California) was utilized in combination with either a balloon-expandable SAPIEN (Edwards Lifesciences) valve or a next-generation low-profile cobalt-chromium bovine pericardial SAPIEN XT (Edwards Lifesciences) valve. RESULTS: Percutaneous valve replacement was successful in all 25 high-risk patients. Aortic valve area increased from 0.59 +/- 0.15 cm(2) to 1.60 +/- 0.27 cm(2). In this high-risk cohort (Society of Thoracic Surgeons and logistic EuroSCORE estimates of surgical mortality were 8.9% and 21.0%, respectively), 30-day mortality was 0%. CONCLUSIONS: Technical and procedural advances in catheter systems and prosthetic valves designed for percutaneous aortic valve delivery may contribute to increased procedural success and improved clinical outcomes.

Endovascular balloon occlusion for catheter-induced large artery perforation in the catheterization laboratory.

BACKGROUND: Vessel perforation is a complication that cannot be completely avoided in the setting of endovascular procedures. When a large noncompressible artery is disrupted, uncontrolled bleeding may lead to hemodynamic collapse. Endovascular occlusion may provide rapid control of hemorrhage and facilitate definitive therapy; yet, occlusion balloons are not commonly utilized in the cardiac catheterization laboratory. METHODS: We describe our experience with the use of dedicated occlusion balloons for the management of catheter-induced major bleeding events. Endovascular occlusion was utilized to control severe bleeding in five patients with perforation of the aorta, iliac, femoral, or pulmonary artery. RESULTS: Acute control of hemorrhage was achieved in all patients with hemodynamic stabilization in four of five cases. Endovascular balloon occlusion facilitated definitive therapy with surgical repair in two patients, covered stent deployment in one patient and transcatheter vessel occlusion in one patient. Care was withdrawn in one elderly patient with multiple comorbidities. All four patients who survived the procedure were discharged alive from the hospital. CONCLUSIONS: In most cases of severe catheter-induced bleeding, endovascular balloon occlusion provide a safe, rapid, and effective means of temporary bleeding control.